

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**MicroPort NeuroTech Limited**

**微創腦科學有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2172)**

## **PRELIMINARY ESTIMATION FOR 2024 INTERIM RESULTS**

This announcement is made by MicroPort NeuroTech Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group and other currently available information for the six months ended 30 June 2024 (the “**Reporting Period**”), the Group is expected to record a revenue of approximately RMB400 million to RMB410 million, representing an increase of approximately 34% to 37% as compared to that of the six months ended 30 June 2023 (the “**Prior-year Period**”).

Based on currently available information, the Board considers that the aforementioned expected increase in the revenue of the Group is principally attributable to the following reasons:

- (1) The Group achieved a breakthrough progress in its overseas business, resulting an expected increase in the revenue for the Reporting Period by approximately 70% to 90% as compared with that for the Prior-year Period;
- (2) Our intracranial atherosclerotic stenosis products (including Bridge<sup>®</sup> Rapamycin Target Eluting Vertebral Artery Stent System, APOLLO<sup>™</sup> Intracranial Stent System, etc.) continued to increase the market share and achieved significant growth in revenue;

- (3) Benefitting from winning the volume-based procurement (VBP) bid to accelerate the development of new markets, our coil products (including NUMEN<sup>®</sup> Coil Embolization System, etc.) played an important role in the increase of revenue;
- (4) The hospital admission and clinical usage have been accelerated for multiple acute ischemic stroke products and access products (including Neurohawk<sup>®</sup> Stent Thrombectomy Device, X-track<sup>®</sup> Distal Access Catheter, U-track<sup>®</sup> Intracranial Support Catheter System, etc.) approved and launched since 2022, contributing to the Group's revenue growth.

As at the date of this announcement, the Company is still in the process of preparing and finalizing the unaudited interim results of the Group for the six months ended 30 June 2024 (the “**2024 Interim Results**”). The information contained in this announcement is only a preliminary assessment made by the Board based on the latest management accounts of the Group which have not been audited or reviewed by the independent auditors or the audit committee of the Company. Shareholders and potential investors of the Company are advised to read the Company's 2024 Interim Results carefully, which is expected to be published by the end of August 2024.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**MicroPort NeuroTech Limited**  
**Dr. Chang Zhaohua**  
*Chairman*

Hong Kong, 2 July 2024

*As at the date of this announcement, Mr. Xie Zhiyong and Mr. Wang Yiqun Bruce are the executive directors; Dr. Chang Zhaohua, Mr. Sun Qingwei, Mr. Wang Lin and Ms. Wu Xia are the non-executive directors; and Dr. Xu Yi, Dr. Zhang Haixiao, and Mr. Fan Xin are the independent non-executive directors.*